{"contentid": 488254, "importid": NaN, "name": "Cidara inks up to $780 million deal for antiviral conjugates", "introduction": "Shares of US biotech Cidera Therapeutics were up nearly 11% at $2.95 6% pre-market on Monday, as it revealed an exclusive worldwide license and collaboration with Janssen Pharmaceuticals.", "content": "<p>Shares of US biotech Cidera Therapeutics (Nasdaq: CDTX) were up nearly 11% at $2.95 6% pre-market on Monday, as it revealed an exclusive worldwide license and collaboration with Janssen Pharmaceuticals, part of US healthcare giant Johnson &amp; Johnson (NYSE: JNJ), to develop and commercialize Cidara&rsquo;s Cloudbreak antiviral conjugates (AVCs) for the prevention and treatment of seasonal and pandemic influenza. This agreement was facilitated by Johnson &amp; Johnson Innovation.</p>\n<p>Under the collaboration, Cidara will be responsible for the development and manufacturing of the first influenza AVC, CD388, into the clinic and through Phase II clinical development, and Janssen for late-stage development, manufacturing, registration and global commercialization.</p>\n<h2><strong>Financial terms of the collaboration</strong></h2>\n<p>Cidara will receive an upfront payment of $27 million and Janssen will fund all future research, development, manufacturing and commercialization for CD388. In addition, Cidara is eligible to receive up to an aggregate of $753 million in budgeted R&amp;D funding and in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales in the mid to high single digits. Cidara has the option to co-detail CD388 in the USA.</p>\n<p>Cidara expects to file an Investigational New Drug Application for CD388 with the US Food and Drug Administration by the end of&nbsp;</p>\n<p>&ldquo;In the US alone, there are an estimated 100 million individuals who are at high risk for complications due to seasonal influenza, and each year there are up to 650,000 influenza deaths worldwide. This collaboration represents a significant advancement toward fulfilling our vision of providing universal, seasonal protection against all seasonal and pandemic strains of influenza,&rdquo; said Jeffrey Stein, president and chief executive of Cidara.</p>\n<p>\"We believe Janssen, with its expertise in the development and commercialization of vaccines and therapies for viral respiratory diseases, is the ideal partner to rapidly advance CD388. Importantly, this agreement validates our Cloudbreak antiviral platform as we continue to advance our AVC programs in RSV, HIV and SARS-CoV-2,&rdquo; Dr Stein noted.</p>", "date": "2021-04-06 10:26:00", "meta_title": "Cidara inks up to $780 million deal for antiviral conjugates", "meta_keywords": "Cidara Therapeutics, Janssen, Johnson & Johnson, Cloougbreak, Antiviral, Conjugates, Collaboration", "meta_description": "Cidara inks up to $780 million deal for antiviral conjugates", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-05 16:07:23", "updated": "2021-04-06 10:26:06", "access": NaN, "url": "https://www.thepharmaletter.com/article/cidara-inks-up-to-780-million-deal-for-antiviral-conjugates", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "cidara_company.png", "image2id": "janssen_johnson_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals", "topic_tag": "Deals, Licensing, One to Watch Companies, Research", "geography_tag": "USA", "company_tag": "Cidara Therapeutics, Janssen, Johnson & Johnson", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-06 10:26:00"}